BMC Complement Altern Med
April 2017
Background: Although the dopamine precursor L-3, 4-dihydroxyphenylalanine ( -dopa) remains the gold standard pharmacological therapy for patients with Parkinson's disease (PD), long-term treatment with this drug has been known to result in several adverse effects, including -dopa-induced dyskinesia (LID). Recently, our group reported that KD5040, a modified herbal remedy, had neuroprotective effects in both in vitro and in vivo models of PD. Thus, the present study investigated whether KD5040 would have synergistic effects with -dopa and antidyskinetic effects caused by -dopa as well.
View Article and Find Full Text PDF